Suicide Risk From Weight-Loss Drugs Prompts More EU Questions

Altimmune Jumps 66% After Positive Results for Its Obesity Drug

Forget Novo, Rolls-Royce Is Europe’s Best Stock This Year

Long-Time Novo Bull Slashes Stake Citing Weight-Loss Drug Hype

Ozempic Maker Novo Nordisk Invests $2.3 Billion in France Site

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype

Novo Nordisk Staff Get Free Wegovy As a Perk If They Need It

Germany Mulls Obesity Drug Export Ban as EU Confronts Shortage

Novo Shares Rise After Wegovy Demonstrates Heart Benefit in Trial

Trump’s Bet in Iowa, Wegovy Study: Your Saturday US Briefing

Wegovy Study Bolsters Use In Patients With Obesity and Heart Disease

Weight-Loss Drugs Among the Most Sought-After New Corporate Benefits